Mandibular NeoplasmsNCT02745288
Inferior Alveolar Nerve Block for Intraoperative Analgesia for Maxillofacial Cancer Surgery - RCT
A study testing inferior alveolar nerve block in people with Mandibular Neoplasms, run by Tata Memorial Centre at 1 site in India.
Trial summary
Mandibular resection which is an important component of maxillofacial cancer surgery is an extremely painful procedure associated with severe sympathetic response needing high doses of opioids. Inferior alveolar nerve block is a common nerve block used by dentists for mandibular dental extractions. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Mandibular Neoplasms
- What is being tested?
- inferior alveolar nerve block
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteIndia
- Study dates
- Jun 2016to Oct 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients between the age of 18 and 75 yrs classified as ASA I and II physical status requiring maxillofacial cancer surgery requiring unilateral mandibular resection and unilateral neck dissection
Who cannot join
- - surgery involving upper alveolar / maxillary resection
- patients with BMI below 18kg/m2 and above 30kg/m2
- allergy to local anaesthetic agent
- Inability to give inferior alveolar nerve block due to any cause e.g. restricted mouth opening, obscured landmark or infection at site
- pregnant women
- patients unable to give valid consent e.g. patients with learning difficulties
Show all 9Show fewer
- patients on medications for hypertension
- patients with preoperative pain requiring regular pain medications
- uncontrolled haemodynamic status e.g. baseline arterial blood pressure above 160 /90 and baseline HR above 100 /min
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Inferior Alveolar Nerve Block for Intraoperative Analgesia for Maxillofacial Cancer Surgery Requiring Unilateral Mandibular Resection-A Randomized Controlled Study
Mandibular resection which is an important component of maxillofacial cancer surgery is an extremely painful procedure associated with severe sympathetic response needing high doses of opioids. Inferior alveolar nerve block is a common nerve block used by dentists for mandibular dental extractions. The aim of this trial is to study the effect of this block for intraoperative analgesia in maxillofacial cancer surgeries requiring unilateral mandibular resection.
Read the detailed description
All adult patients below 75yrs of age scheduled for maxillofacial surgery will be screened for inclusion and exclusion criteria.
Written informed consent will be taken one day prior to surgery. Consenting subjects will be randomized after induction of anaesthesia to study or control arm.
The duration of the study is from induction of anaesthesia to the completion of primary tumour removal and neck dissection
Study procedure: Ipsilateral Inferior alveolar nerve block A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.
The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood.
Control arm will not receive any intervention. The study investigator will give a mock injection for blinding of the attending anaesthetist
The study procedure will be done by the study investigators 10 -30 minutes prior to commencing surgery for primary tumour.
Account of procedure:
All patients will have standard conduct of anaesthesia except for the alveolar nerve injection in the study group.
All patients will have the minimum standard monitoring of pulse oximeter, electrocardiogram, capnography and non invasive blood pressure monitoring.
Blood pressure and heart rate will be recorded every 5 min interval from the beginning till completion of primary tumor excision and neck dissection
Induction of anaesthesia: IV fentanyl 2 mcg/kg, IV Propofol 2 -3 mg/kg. IV neuromuscular blocking agent used will be Inj vecuronium bromide in the dose of 0.1 mg /kg. All patients will have standard airway management at the discretion of the attending anaesthesiologist.
Intraoperative maintenance of anaesthesia will be as follows
- Controlled ventilation with isoflurane in air / oxygen with minimal alveolar concentration of 0.8 -1.2
- Intraoperative analgesic - IV fentanyl in boluses of 1 mcg/kg at the discretion of the anaesthetist based on the haemodynamic response till the completion of primary tumour removal and neck dissection. Thereafter, the choice of analgesic will be left to the anaesthetist
- In case of uncontrolled sympathetic response (hypertension and/or tachycardia) to surgery not controlled by IV fentanyl (10 mcg/kg ), rescue intraoperative analgesic/ anaesthetic (e.g.IV morphine, IV diclofenac, IV dexmedetomide, IV propofol, increase in inhalational anaesthetic concentration, etc) or vasoactive agents (e.g.IV Esmolol, IV Nitroglycerin, etc) may be used. This will be noted in the Case record form.
Information will be collected as per Case Record form by the investigator. Any deviation from protocol will be recorded.
Sample size calculation Based on the average fentanyl requirement 340mcg found in pilot data, to detect 25% reduction in fentanyl requirement in the study group compared to control group, with 80% power and level of significance of 5% ,the sample size calculated was 22 in each group.
Statistical Analysis The fentanyl requirement in the two groups, maximum heart rate and maximum blood pressure will be will be compared using students t test Other variables will be described as numbers and percentage
Demographic ,clinical and disease relate variable will be present as frequency (percentage) and mean (S.D.) or median as appropriate.
Two group comparisons will be made using independent t-test or Man Whitney U test as per distribution of the data.
P-value< 0.05 will be considered statistical significant. Repeated measures ANOVA will be used to compare change of blood pressure and heart rate from baseline at various time points.
- Conditions
- Mandibular Neoplasms
- Being tested
- inferior alveolar nerve block
- Medical subject headings
- Mandibular Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
inferior alveolar nerve blockProcedure or surgery
A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.
The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood.
| Study group | Role | What they receive |
|---|---|---|
| Nerve block | Experimental | This arm will receive inferior alveolar nerve block Receives: Procedure: inferior alveolar nerve block |
| control | No intervention | Control arm will not receive inferior alveolar block |
What is being measured
The primary outcome is the main question the study is designed to answer.
IV fentanyl requirement during primary tumour removal
The total IV fentanyl dose required during primary tumour removal will be noted
Measured: From start to finish ofprimary tumour removal procedure
Secondary outcomes (4)
IV fentanyl requirement during neck dissection and primary tumour removal
The total IV fentanyl dose required during neck dissection and primary tumour removal will be noted
Measured: From start to finish of neck dissection and primary tumour removal
Maximum change in heart rate from baseline during primary tumour removal
Measured: From start to finish of primary tumour removal procedure
Maximum change in blood pressure from baseline during primary tumour removal
Measured: From start to finish of primary tumour removal procedure
Need for rescue analgesics or vasoactive agents during primary tumour removal
Measured: From start to finish of primary tumour removal procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2016 (estimated)
- Study startJun 2016
- Primary completionOct 2016
- Study completionOct 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mandibular NeoplasmsStudies of the same condition, open and under way.
- More trials run by Tata Memorial CentreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tata Memorial Centre
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Madhavi Shetmahajan, Tata Memorial Centre
- Investigators
- Madhavi Shetmahajan, MD, Principal investigator, Tata Memorial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02745288
- Sponsor's protocol ID
- 1648
- Status last verified
- Nov 2016
- First submitted
- 15 Apr 2016
- Last updated
- 22 Nov 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Nov 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Inferior Alveolar Nerve Block for Intraoperative Analgesia for Maxillofacial Cancer Surgery Requiring Unilateral Mandibular Resection-A Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT02745288
- Acronym / sponsor ID
- 1648
- Conditions
- Mandibular Neoplasms
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Tata Memorial CentreUniversity, hospital or other
- Study start
- Jun 2016
- Primary completion
- Oct 2016 (actual)
- Study completion
- Oct 2016 (actual)
- First posted
- 20 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mandibular resection which is an important component of maxillofacial cancer surgery is an extremely painful procedure associated with severe sympathetic response needing high doses of opioids. Inferior alveolar nerve block is a common nerve block used by dentists for mandibular dental extractions. The aim of this trial is to study the effect of this block for intraoperative analgesia in maxillofacial cancer surgeries requiring unilateral mandibular resection.
Detailed description
All adult patients below 75yrs of age scheduled for maxillofacial surgery will be screened for inclusion and exclusion criteria.
Written informed consent will be taken one day prior to surgery. Consenting subjects will be randomized after induction of anaesthesia to study or control arm.
The duration of the study is from induction of anaesthesia to the completion of primary tumour removal and neck dissection
Study procedure: Ipsilateral Inferior alveolar nerve block A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.
The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood.
Control arm will not receive any intervention. The study investigator will give a mock injection for blinding of the attending anaesthetist
The study procedure will be done by the study investigators 10 -30 minutes prior to commencing surgery for primary tumour.
Account of procedure:
All patients will have standard conduct of anaesthesia except for the alveolar nerve injection in the study group.
All patients will have the minimum standard monitoring of pulse oximeter, electrocardiogram, capnography and non invasive blood pressure monitoring.
Blood pressure and heart rate will be recorded every 5 min interval from the beginning till completion of primary tumor excision and neck dissection
Induction of anaesthesia: IV fentanyl 2 mcg/kg, IV Propofol 2 -3 mg/kg. IV neuromuscular blocking agent used will be Inj vecuronium bromide in the dose of 0.1 mg /kg. All patients will have standard airway management at the discretion of the attending anaesthesiologist.
Intraoperative maintenance of anaesthesia will be as follows
- Controlled ventilation with isoflurane in air / oxygen with minimal alveolar concentration of 0.8 -1.2
- Intraoperative analgesic - IV fentanyl in boluses of 1 mcg/kg at the discretion of the anaesthetist based on the haemodynamic response till the completion of primary tumour removal and neck dissection. Thereafter, the choice of analgesic will be left to the anaesthetist
- In case of uncontrolled sympathetic response (hypertension and/or tachycardia) to surgery not controlled by IV fentanyl (10 mcg/kg ), rescue intraoperative analgesic/ anaesthetic (e.g.IV morphine, IV diclofenac, IV dexmedetomide, IV propofol, increase in inhalational anaesthetic concentration, etc) or vasoactive agents (e.g.IV Esmolol, IV Nitroglycerin, etc) may be used. This will be noted in the Case record form.
Information will be collected as per Case Record form by the investigator. Any deviation from protocol will be recorded.
Sample size calculation Based on the average fentanyl requirement 340mcg found in pilot data, to detect 25% reduction in fentanyl requirement in the study group compared to control group, with 80% power and level of significance of 5% ,the sample size calculated was 22 in each group.
Statistical Analysis The fentanyl requirement in the two groups, maximum heart rate and maximum blood pressure will be will be compared using students t test Other variables will be described as numbers and percentage
Demographic ,clinical and disease relate variable will be present as frequency (percentage) and mean (S.D.) or median as appropriate.
Two group comparisons will be made using independent t-test or Man Whitney U test as per distribution of the data.
P-value< 0.05 will be considered statistical significant. Repeated measures ANOVA will be used to compare change of blood pressure and heart rate from baseline at various time points.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nerve block | Experimental | Procedure: inferior alveolar nerve blockThis arm will receive inferior alveolar nerve block |
| control | No intervention | –Control arm will not receive inferior alveolar block |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- All patients between the age of 18 and 75 yrs classified as ASA I and II physical status requiring maxillofacial cancer surgery requiring unilateral mandibular resection and unilateral neck dissection
Key exclusion criteria (9 listed)
- - surgery involving upper alveolar / maxillary resection
- patients with BMI below 18kg/m2 and above 30kg/m2
- allergy to local anaesthetic agent
- Inability to give inferior alveolar nerve block due to any cause e.g. restricted mouth opening, obscured landmark or infection at site
- pregnant women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| inferior alveolar nerve blockA long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method. The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood. | Procedure or surgery | Nerve block |
Primary outcome
IV fentanyl requirement during primary tumour removal
Time frame: From start to finish ofprimary tumour removal procedure
The total IV fentanyl dose required during primary tumour removal will be noted
4 secondary outcomes
IV fentanyl requirement during neck dissection and primary tumour removal
Time frame: From start to finish of neck dissection and primary tumour removal
Maximum change in heart rate from baseline during primary tumour removal
Time frame: From start to finish of primary tumour removal procedure
Maximum change in blood pressure from baseline during primary tumour removal
Time frame: From start to finish of primary tumour removal procedure
Need for rescue analgesics or vasoactive agents during primary tumour removal
Time frame: From start to finish of primary tumour removal procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Nov 2016.
- Individual participant dataSharing planned: No
Related trials for Mandibular Neoplasms
Not yet recruitingPhase 1/2
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Recruiting
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
Head and Neck Cancer
Recruiting
Mandibular Reconstruction Preplanning (ViPMR)
Oral Cavity Cancer, Oral Cancer
Active, not recruiting
Bone Defects Reconstruction After Dentigerous Cyst Enucleation With Autogenous Demineralized Dentin Matrix- ADDM and Advanced Platelet-Rich Fibrin- A-PRF.
Impact Molar, Mandible Cyst
Recruiting
AI-based Physiotherapy for Oral Cancer Patients
Oral Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Madhavi Shetmahajan, MD principal investigator
Tata Memorial Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing inferior alveolar nerve block in people with Mandibular Neoplasms, run by Tata Memorial Centre at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
IV fentanyl requirement during primary tumour removal (time frame: From start to finish ofprimary tumour removal procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Nov 2016.